Feng Zhang (Susan Walsh/AP Images)
Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company
After Sigilon Therapeutics’ $126 million IPO last December, COO Devyn Smith started getting calls. Job offers, mostly, for this biotech or that, none that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
